| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Zadaxin (Thymalfasin) Approved In Thailand, Laos And Malta For Hepatitis B And C SAN MATEO, CA -- March 17, 2000 -- SciClone Pharmaceuticals announced that Zadaxin, the company's lead immunotherapy, has been approved for marketing in Thailand, Laos and Malta. Zadaxin now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatitis C. SciClone has filed for Zadaxin marketing approval in 18 additional countries. Hepatitis B and hepatitis C are highly infectious liver diseases that can lead to cirrhosis, liver cancer and death. Worldwide, there are approximately 350 million long-term carriers of the hepatitis B virus, including approximately 1.2 million in the U.S. Approximately 170 million people worldwide are infected with the hepatitis C virus, including 4 million in the U.S. and 5 million in Europe. Many patients with cancer and chronic infectious diseases have an impaired immune system. Zadaxin significantly enhances the immune system's ability to recognize and destroy cancerous and infected cells. Zadaxin immunotherapy is in late-stage development for cancer and viral hepatitis worldwide. SciClone Pharmaceuticals is a global biopharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. The Company has focused its current product development and commercialization activities on cancer, hepatitis B, hepatitis C, drug-resistant tuberculosis and cystic fibrosis. Related Links: Zadaxin and SciClone Pharmaceuticals.
|